AR-Aid Patient Management Tool
In the clinical trial,
Elevation of bilirubin reported in patients with R/R AML
All grades |
≥Grade 3 |
---|---|
81 |
15 |
When bilirubin is elevated to greater than 3× the upper limit of normal (ULN) and sustained for ≥2 weeks without elevated transaminases or other hepatic disorders:
Download our IDHIFA® wallet cards, printable cards for patients and caregivers to show to their non-regular healthcare providers. These printable resources also include information about differentiation syndrome and other ARs associated with IDHIFA®.
IDHIFA® Wallet Cards
Eligibility
Patients must meet the following criteria to enroll:
Program Benefits
Program Timing
Additional Terms and Conditions of the Celgene Commercial Co-pay Programs
© 2017 Celgene Corporation 06/17 US-CELG170216
This site is intended for U.S. audiences only.